Tesamorelin + Ipamorelin
AKA Tesa/Ipa
Last reviewed 2026-10-30
Our read Opinion
An upgrade pitch on CJC/Ipa using an approved ingredient.
Claims made by sellers, clinics and users. Not verified.
Visceral (belly) fat reduction plus a broader GH boost.
Swaps CJC-1295 for tesamorelin, the only FDA-approved GHRH analog, on the same 'GHRH + ghrelin-pathway' logic.
Evidence level: Small/early human studies
Tesamorelin alone has RCT data for visceral fat in HIV lipodystrophy. No published human trials of this combination.
Tesamorelin is FDA approved for one narrow indication; ipamorelin is not approved and remains on Category 2 (verify).
Also sold pre-mixed as Tesamorelin + Ipamorelin Blend →Statuses change; check the linked primary sources.
Borrowing tesamorelin's credibility doesn't transfer to the combination.
| Field | Tesamorelin | Ipamorelin |
|---|---|---|
| Type | FDA Approved | Research Only |
| Regulatory status | FDA-approved (Egrifta formulations) | Not FDA-approved; no verified marketing authorization |
| Compounding status | Approved product (not applicable) | Not cleared (advisory panel rejected) |
| FDA-approved indications | Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy; not indicated for weight-loss management. | None |
| Categories | Growth hormone axis | Growth hormone axis |
| Claimed uses |
|
|
| Mechanism | Growth hormone-releasing hormone analogue that stimulates pituitary growth hormone secretion and increases IGF-1. | Ghrelin-receptor agonist that stimulates growth-hormone release and can affect gastrointestinal motility. Hormone release alone does not establish anti-aging benefit. |
| Evidence level | Human RCTs (approved use) | Small/early human studies |
| Evidence / Hype (opinion) | Evidence Hype | Evidence Hype |
| Momentum (opinion) | Steady | Watch |
| Routes | Injection | — |
| WADA | Prohibited | Prohibited |
| Where it stands (opinion) | A narrowly indicated approved medicine, not a general anti-aging treatment. WADA 2026 S2.2.4 prohibits growth hormone-releasing factors, including tesamorelin. | Historical phase 2 research does not establish wellness efficacy. Its 503A nomination was withdrawn; acetate remains Category 2 under 503B, and WADA 2026 S2.2.4 prohibits it. |
| Last reviewed | 2026-10-30 | 2026-10-30 |
| News (30d) | 0 | 0 |
No news yet for these peptides.
Information only. Not medical advice. Describing a stack is not a recommendation to combine, obtain or use any compound. Ratings and "Our Take" are editorial opinion. Full disclaimer.